Recombinant Plasma Protein Therapeutics Market (Drug Class - Recombinant Coagulation Factors, Human C1 Esterase Inhibitor; Cell Line - Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Others; Indication - Hemophilia A, Hemophilia B, Von Willebrand Disease) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2030

Description

Global Recombinant Plasma Protein Therapeutics Market - Snapshot

The global recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases. Additionally, steady increase in the number of patients with rare hematological diseases and product approvals by regulatory authorities such as the Food and Drug Administration (FDA), European Commission, and Ministry of Health, Labour and Welfare (Japan) are anticipated to drive the market significantly during the forecast period. However, the high cost of treatment and availability of alternative therapies are likely to restrain the global market.

The global recombinant plasma protein therapeutics market has been segmented based on drug class, cell line, and indication. Based on drug class, the market has been classified into recombinant coagulation factors and human C1 esterase inhibitor. The recombinant coagulation factors segment has been further sub-segmented into recombinant coagulation factor VIII, recombinant coagulation factor IX, recombinant coagulation factor VIIa, and others. The recombinant coagulation factor VIII sub-segment is projected to account for a major share of the recombinant coagulation factors segment of the market by 2026, due to the increase in number of hemophilia A cases across the globe, new product launches, and use of recombinant plasma protein therapies for the treatment of hemophilia A. The recombinant coagulation factor VIIa sub-segment is anticipated to expand at a steady pace during the forecast period. In terms of cell line, the market has been categorized into Chinese hamster ovary (CHO) cell line, baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, and others. The Chinese hamster ovary (CHO) cell line segment is expected to expand at a prominent CAGR due to an increase in the utilization of CHO cell lines for manufacturing therapeutic products. Based on indication, the market has been segregated into hemophilia A, hemophilia B, Von Willebrand disease, and others 

Based on region, the global recombinant plasma protein therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a prominent share of the global market. In North America, the market in the U.S. is anticipated to expand at a rapid pace, due to a surge in the demand for recombinant coagulation factor VII and IX, rise in the emphasis on the management of rare diseases such as hemophilia A, hemophilia B, and Von Willebrand disease, and increase in the number of market players offering recombinant plasma proteins. Additionally, market players are focused on increasing global presence through distribution agreements, partnerships, and geographical expansion. 

In Europe, increasing number of established biotechnology & pharmaceutical companies and research institutes, universities, and commercial players are obtaining funds for research & development studies in the field of recombinant DNA technology, which in turn is projected to boost the market. Furthermore, advancements in genetic engineering and biotechnology in countries such as Germany, U.K., and France significantly drive the opportunities of developing new therapeutics products for diseases. Moreover, in January 2017, CSL Limited received approval and marketing authorization from European Commission for AFSTYLA, indicated for the treatment of Hemophilia A. Such approvals increased the availability of drugs in Europe. 

Major players operating in the global recombinant plasma protein therapeutics market include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer Inc.  

Expanding Cases of Hemophilia among many Individuals to Bring Profitable Growth for the Recombinant Plasma Protein Therapeutics Market

The recombinant plasma protein therapeutics market will gain considerable growth opportunities during the forecast period of 2018-2026 owing to an increase in the demand for advanced therapies across a large chunk of the global populace. Technological advancements and an increase in research and development activities coupled with the rising geriatric population are some major factors that will influence the growth to a considerable extent.

Plasma proteins are prominently utilized in replacement therapies. These therapies are used for treating rare conditions such as hemophilia and other bleeding disorders. The expanding number of rare hematology cases will bring promising growth.

Diverse awareness campaigns organized by various government and non-government organizations about hemophilia A and hemophilia B will bring tremendous growth opportunities for the recombinant plasma protein therapeutics market Furthermore, quick approvals from regulatory authorities are also helping the recombinant plasma protein therapeutics market to gain good growth opportunities. These factors bode well for the growth.

Rising investment in research and development activities from the players in the recombinant plasma protein therapeutics market will serve as a vital growth-generating aspect. The players invest in these activities for formulating new developments and strategies that help in increasing the demand for recombinant plasma protein therapeutics.  These activities eventually help in sowing the seeds of growth.

The players also indulge in strategic collaborations. The collaborations strengthen the position of manufacturers in the recombinant plasma protein therapeutics market, which ultimately results in an increase in the growth rate.

The COVID-19 pandemic will not have much impact on the growth of the recombinant plasma protein therapeutics market as it comes under healthcare services and is exempt from all sorts of lockdown restrictions. The lockdown restrictions imposed by numerous countries at the start of the pandemic in 2020 had a minimal negative effect on the recombinant plasma protein therapeutics market.

The global recombinant plasma protein therapeutics market has been segmented as below:

Drug Class

  • Recombinant Coagulation Factors
  • Recombinant Coagulation Factor VIII
  • Recombinant Coagulation Factor IX
  • Recombinant Coagulation Factor VIIa
  • Others
  • Human C1 Esterase Inhibitor

Cell Line

  • Chinese Hamster Ovary (CHO) Cell Line
  • Baby Hamster Kidney (BHK) Cell Line
  • Human Embryonic Kidney (HEK) Cell Line
  • Others

Indication

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
                          4.3.1.1 Shift from use of Plasma Derived Proteins to Recombinant Therapies
                          4.3.1.2 Rising Awareness about Rare Disease Management
                          4.3.1.3 Increasing Focus on Investments in Rare Disease
            4.3.2. Restraints
                          4.3.2.1 High Cost of Treatment
                          4.3.2.2 Availability of Alternative Therapies
            4.3.3. Opportunities
                          4.3.3.1 Growth Opportunities in Developing Markets
                          4.3.3.2 Strategic Approaches such as Partnership and Distribution Agreements
     4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016–2026

5. Key Insights
     5.1. New Product Launch and Regulatory Approvals
     5.2. Key Mergers & Acquisitions 
     5.3. Regulatory Scenario by Region/Country

6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Recombinant Coagulation Factors
                          6.3.1.1. Recombinant Coagulation Factor VIII
                          6.3.1.2. Recombinant Coagulation Factor IX
                          6.3.1.3. Recombinant Coagulation Factor VIIa
                          6.3.1.4. Others
            6.3.2. Human C1 Esterase Inhibitor
     6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class 

7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
            7.3.1. Chinese Hamster Ovary (CHO) Cell Line
            7.3.2. Baby Hamster Kidney (BHK) Cell Line
            7.3.3. Human Embryonic Kidney (HEK) Cell Line
            7.3.4. Others
     7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line 

8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
            8.3.1. Hemophilia A
            8.3.2. Hemophilia B
            8.3.3. Von Willebrand Disease
            8.3.4. Others
     8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication 

9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region

10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
            10.2.1. Recombinant Coagulation Factors
                      10.2.1.1. Recombinant Coagulation Factor VIII
                      10.2.1.2. Recombinant Coagulation Factor IX
                      10.2.1.3. Recombinant Coagulation Factor VIIa
                      10.2.1.4. Others
            10.2.2. Human C1 Esterase Inhibitor
     10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
            10.3.1. Chinese Hamster Ovary (CHO) Cell Line
            10.3.2. Baby Hamster Kidney (BHK) Cell Line
            10.3.3. Human Embryonic Kidney (HEK) Cell Line
            10.3.4. Others
     10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
            10.4.1. Hemophilia A
            10.4.2. Hemophilia B
            10.4.3. Von Willebrand Disease
            10.4.4. Others
     10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
            10.6.1. By Drug Class 
            10.6.2. By Cell Line 
            10.6.3. By Indication 
            10.6.4. By Country

11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Recombinant Coagulation Factors
                      11.2.1.1. Recombinant Coagulation Factor VIII
                      11.2.1.2. Recombinant Coagulation Factor IX
                      11.2.1.3. Recombinant Coagulation Factor VIIa
                      11.2.1.4. Others
            11.2.2. Human C1 Esterase Inhibitor
     11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
            11.3.1. Chinese Hamster Ovary (CHO) Cell Line
            11.3.2. Baby Hamster Kidney (BHK) Cell Line
            11.3.3. Human Embryonic Kidney (HEK) Cell Line
            11.3.4. Others
     11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
            11.4.1. Hemophilia A
            11.4.2. Hemophilia B
            11.4.3. Von Willebrand Disease
            11.4.4. Others
     11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
            11.6.1. By Drug Class 
            11.6.2. By Cell Line 
            11.6.3. By Indication 
            11.6.4. By Country/Sub-region

12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Recombinant Coagulation Factors
                      12.2.1.1. Recombinant Coagulation Factor VIII
                      12.2.1.2. Recombinant Coagulation Factor IX
                      12.2.1.3. Recombinant Coagulation Factor VIIa
                      12.2.1.4. Others
            12.2.2. Human C1 Esterase Inhibitor
     12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
            12.3.1. Chinese Hamster Ovary (CHO) Cell Line
            12.3.2. Baby Hamster Kidney (BHK) Cell Line
            12.3.3. Human Embryonic Kidney (HEK) Cell Line
            12.3.4. Others
     12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
            12.4.1. Hemophilia A
            12.4.2. Hemophilia B
            12.4.3. Von Willebrand Disease
            12.4.4. Others
     12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
            12.6.1. By Drug Class 
            12.6.2. By Cell Line 
            12.6.3. By Indication 
            12.6.4. By Country/Sub-region

13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
     13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Recombinant Coagulation Factors
                      13.2.1.1. Recombinant Coagulation Factor VIII
                      13.2.1.2. Recombinant Coagulation Factor IX
                      13.2.1.3. Recombinant Coagulation Factor VIIa
                      13.2.1.4. Others
            13.2.2. Human C1 Esterase Inhibitor
     13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
            13.3.1. Chinese Hamster Ovary (CHO) Cell Line
            13.3.2. Baby Hamster Kidney (BHK) Cell Line
            13.3.3. Human Embryonic Kidney (HEK) Cell Line
            13.3.4. Others
     13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
            13.4.1. Hemophilia A
            13.4.2. Hemophilia B
            13.4.3. Von Willebrand Disease
            13.4.4. Others
     13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Cell Line 
            13.6.3. By Indication 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
     14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
            14.2.1. Recombinant Coagulation Factors
                      14.2.1.1. Recombinant Coagulation Factor VIII
                      14.2.1.2. Recombinant Coagulation Factor IX
                      14.2.1.3. Recombinant Coagulation Factor VIIa
                      14.2.1.4. Others
            14.2.2. Human C1 Esterase Inhibitor
     14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
            14.3.1. Chinese Hamster Ovary (CHO) Cell Line
            14.3.2. Baby Hamster Kidney (BHK) Cell Line
            14.3.3. Human Embryonic Kidney (HEK) Cell Line
            14.3.4. Others
     14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
            14.4.1. Hemophilia A
            14.4.2. Hemophilia B
            14.4.3. Von Willebrand Disease
            14.4.4. Others
     14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
     14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
            14.6.1. By Drug Class 
            14.6.2. By Cell Line 
            14.6.3. By Indication 
            14.6.4. By Country/Sub-region

15. Competitive Landscape
     15.1. Market Player – Competition Matrix (By Tier and Size of companies)
     15.2. Market Share Analysis By Company (2016)
     15.3. Company Profiles
            15.3.1. CSL Limited
                      15.3.1.1. Company Details
                      15.3.1.2. Products Portfolio
                      15.3.1.3. Financial Overview
                      15.3.1.4. Strategic Overview
                      15.3.1.5. SWOT Analysis
            15.3.2. Shire (Takeda Pharmaceutical Company Limited)
                      15.3.2.1. Company Details
                      15.3.2.2. Products Portfolio
                      15.3.2.3. Financial Overview
                      15.3.2.4. Strategic Overview
                      15.3.2.5. SWOT Analysis
            15.3.3. Octapharma
                      15.3.3.1. Company Details
                      15.3.3.2. Products Portfolio
                      15.3.3.3. Financial Overview
                      15.3.3.4. Strategic Overview
                      15.3.3.5. SWOT Analysis
            15.3.4. Novo Nordisk A/S
                      15.3.4.1. Company Details
                      15.3.4.2. Products Portfolio
                      15.3.4.3. Financial Overview
                      15.3.4.4. Strategic Overview
                      15.3.4.5. SWOT Analysis
            15.3.5. Bayer AG
                      15.3.5.1. Company Details
                      15.3.5.2. Products Portfolio
                      15.3.5.3. Financial Overview
                      15.3.5.4. Strategic Overview
                      15.3.5.5. SWOT Analysis
            15.3.6. Pfizer Inc.
                      15.3.6.1. Company Details
                      15.3.6.2. Products Portfolio
                      15.3.6.3. Financial Overview
                      15.3.6.4. Strategic Overview
                      15.3.6.5. SWOT Analysis
            15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)
                      15.3.7.1. Company Details
                      15.3.7.2. Products Portfolio
                      15.3.7.3. Financial Overview
                      15.3.7.4. Strategic Overview
                      15.3.7.5. SWOT Analysis
            15.3.8. Aptevo Therapeutics
                      15.3.8.1. Company Details
                      15.3.8.2. Products Portfolio
                      15.3.8.3. Financial Overview
                      15.3.8.4. Strategic Overview
                      15.3.8.5. SWOT Analysis
            15.3.9. Pharming Group NV
                      15.3.9.1. Company Details
                      15.3.9.2. Products Portfolio
                      15.3.9.3. Financial Overview
                      15.3.9.4. Strategic Overview
                      15.3.9.5. SWOT Analysis

Delivery Format : EXCEL/Data Pack

Choose License Type

Checkout Inquiry Sample